Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
“We are excited to write the next chapter of Cytospire’s story with this fantastic group of specialist investors,” said Natalie Mount, Chief Executive Officer of Cytospire Therapeutics. “Immune cell engagers are an important type of cancer immunotherapy, but we know that there are significant limitations from both an efficacy and safety perspective with conventional CD3 T cell engagers. We are building on the growing body of translational and clinical data showing gamma delta T cells are critical components of the anti-cancer immune response, with biology ideally suited to novel cell engagers. The significant fundraise that we are announcing today reflects the quality of our team and our science, and the huge potential of our pan-gamma delta T cell engagers”.
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month